DOP2011000149A - Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia - Google Patents
Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopeniaInfo
- Publication number
- DOP2011000149A DOP2011000149A DO2011000149A DO2011000149A DOP2011000149A DO P2011000149 A DOP2011000149 A DO P2011000149A DO 2011000149 A DO2011000149 A DO 2011000149A DO 2011000149 A DO2011000149 A DO 2011000149A DO P2011000149 A DOP2011000149 A DO P2011000149A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- trombocitopenia
- thrombocitopenia
- reducing
- mortality associated
- thrombocytopenia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen métodos para reducir el riesgo de mortalidad y morbilidad asociadas a trombocitopenia y para reducìr el riesgo de trombocitopenia en pacientes cuyo tratamiento requiere inhibición de la agregación plaquetaría. Los rnétodos involucran la admìnistracïón de una sal farrnacéuticamente aceptable de tirofiban
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11697608P | 2008-11-21 | 2008-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2011000149A true DOP2011000149A (es) | 2011-10-31 |
Family
ID=42198725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2011000149A DOP2011000149A (es) | 2008-11-21 | 2011-05-20 | Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia |
Country Status (18)
Country | Link |
---|---|
US (1) | US20120059036A1 (es) |
EP (1) | EP2355824A4 (es) |
KR (1) | KR20110108330A (es) |
AU (1) | AU2009318101A1 (es) |
BR (1) | BRPI0920984A2 (es) |
CL (1) | CL2011001175A1 (es) |
CO (1) | CO6390039A2 (es) |
CR (1) | CR20110271A (es) |
DO (1) | DOP2011000149A (es) |
EC (1) | ECSP11011152A (es) |
MA (1) | MA32820B1 (es) |
MX (1) | MX2011005376A (es) |
NI (1) | NI201100101A (es) |
PE (1) | PE20110946A1 (es) |
SV (1) | SV2011003915A (es) |
TN (1) | TN2011000256A1 (es) |
WO (1) | WO2010059244A2 (es) |
ZA (1) | ZA201103741B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101996880B1 (ko) | 2018-03-16 | 2019-07-05 | 경성대학교 산학협력단 | 컴파운드 k를 유효성분으로 포함하는 혈소판 감소증 예방 또는 치료용 조성물 |
CN112441962A (zh) * | 2019-09-04 | 2021-03-05 | 武汉武药科技有限公司 | 替罗非班及其纯化方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ239846A (en) | 1990-09-27 | 1994-11-25 | Merck & Co Inc | Sulphonamide derivatives and pharmaceutical compositions thereof |
PT1353694E (pt) * | 2001-01-26 | 2008-03-12 | Schering Corp | Combinações de ezetimiba com aspirina para o tratamento de doenças vasculares |
US6770660B2 (en) | 2002-05-06 | 2004-08-03 | Artery Llc | Method for inhibiting platelet aggregation |
PL376535A1 (pl) * | 2002-09-09 | 2006-01-09 | Trigen Limited | Sole kwasu boronowego i ich zastosowanie w leczeniu zakrzepicy |
US7388021B2 (en) * | 2004-05-12 | 2008-06-17 | Bristol Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
BRPI0516003A (pt) * | 2004-10-12 | 2008-04-29 | Decode Genetics Inc | composto, uso em um composto ou um éster, um sal farmaceuticamente aceitável ou um hidrato do mesmo, formulação farmacêutica, e, método para a triagem in vitro de ligandos de receptor de prostanóide seletivos |
-
2009
- 2009-11-20 KR KR1020117011598A patent/KR20110108330A/ko not_active Application Discontinuation
- 2009-11-20 EP EP09827893A patent/EP2355824A4/en not_active Withdrawn
- 2009-11-20 WO PCT/US2009/006240 patent/WO2010059244A2/en active Application Filing
- 2009-11-20 US US13/130,340 patent/US20120059036A1/en not_active Abandoned
- 2009-11-20 BR BRPI0920984A patent/BRPI0920984A2/pt not_active IP Right Cessation
- 2009-11-20 PE PE2011001062A patent/PE20110946A1/es not_active Application Discontinuation
- 2009-11-20 MX MX2011005376A patent/MX2011005376A/es not_active Application Discontinuation
- 2009-11-20 AU AU2009318101A patent/AU2009318101A1/en not_active Abandoned
-
2011
- 2011-05-19 CL CL2011001175A patent/CL2011001175A1/es unknown
- 2011-05-20 MA MA33876A patent/MA32820B1/fr unknown
- 2011-05-20 NI NI201100101A patent/NI201100101A/es unknown
- 2011-05-20 ZA ZA2011/03741A patent/ZA201103741B/en unknown
- 2011-05-20 DO DO2011000149A patent/DOP2011000149A/es unknown
- 2011-05-20 TN TN2011000256A patent/TN2011000256A1/fr unknown
- 2011-05-23 SV SV2011003915A patent/SV2011003915A/es unknown
- 2011-05-23 CR CR20110271A patent/CR20110271A/es not_active Application Discontinuation
- 2011-06-14 CO CO11073669A patent/CO6390039A2/es not_active Application Discontinuation
- 2011-06-20 EC EC2011011152A patent/ECSP11011152A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20110946A1 (es) | 2012-01-05 |
ZA201103741B (en) | 2012-01-25 |
EP2355824A2 (en) | 2011-08-17 |
BRPI0920984A2 (pt) | 2017-07-11 |
TN2011000256A1 (en) | 2012-12-17 |
MX2011005376A (es) | 2011-10-19 |
CO6390039A2 (es) | 2012-02-29 |
US20120059036A1 (en) | 2012-03-08 |
SV2011003915A (es) | 2011-07-01 |
WO2010059244A3 (en) | 2010-10-14 |
ECSP11011152A (es) | 2011-09-30 |
KR20110108330A (ko) | 2011-10-05 |
CL2011001175A1 (es) | 2011-11-11 |
EP2355824A4 (en) | 2012-11-07 |
AU2009318101A1 (en) | 2010-05-27 |
CR20110271A (es) | 2011-10-13 |
WO2010059244A2 (en) | 2010-05-27 |
NI201100101A (es) | 2011-12-19 |
MA32820B1 (fr) | 2011-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
GT201300234A (es) | Sales de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida | |
EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
CL2013001602A1 (es) | Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. | |
DOP2014000159A (es) | Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre | |
PE20142353A1 (es) | Ansolvatos de sal de noribogaina | |
AR083865A1 (es) | Composicion en gel para preparar un producto alimenticio | |
CL2007003584A1 (es) | Alimento para animales que utiliza krill como toda o parte de una fuente de proteina del alimento que comprende que se usa krill sin caparazon; y metodo para minimizar la reduccion en la tasa de crecimiento de los peces causada por el uso del krill c | |
UY32052A (es) | 5-aminopirazoles sustituidos y uso de los mismos | |
CL2012003031A1 (es) | Un metodo para administrar un lugar de investigacion de semillas. | |
AR082215A1 (es) | Composicion farmaceutica agradable al paladar | |
EA201490199A1 (ru) | Терапевтические способы | |
GT201400042A (es) | Compuesto de benzotiazolona | |
ECSP11011152A (es) | Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia | |
AR094224A1 (es) | Composicion farmaceutica en forma de una suspension oral | |
UY32507A (es) | Una dosis de ave5026 para el tratamiento de trombormbolismo venoso en pacientes con deterioro renal severo | |
AR095594A1 (es) | Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos | |
UY35323A (es) | Derivados sustituidos del ácido bisfenil butanóico como inhibidores de la nep con una mejorada efic acia in vivo | |
CL2008002465A1 (es) | Composición farmacéutica anhidra tópica, que comprende derivados de niacina y un portador aceptable, su aplicacón permite un bienestar sexual mejorado. | |
AR084169A1 (es) | Combinacion que comprende un derivado de la familia de las combretastatinas y cetuximab | |
UY33431A (es) | Sal de tirofibán y uso para reducir la trombacitopenia y mortalidad asociada a la trombocitopenia | |
AR081639A1 (es) | Una sal de tirofiban y uso de una cantidad efectiva de una sal de tirofiban farmaceuticamente aceptable para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia | |
CL2013003268A1 (es) | Uso de una composición que comprende secnidazol y un antibiótico macrólido para preparar un medicamento útil en el tratamiento de infecciones dentales. | |
CR20130687A (es) | Composición farmacéutica para uso en inflamación y dolor | |
CL2016000226A1 (es) | Una formulación para el manejo de la obesidad que comprende lactobacillus sp. dsm22105, como principio activo; pulpa de arándano, gelatina, pectina, benzoato de sodio, y agua purificada. |